IMMU: Study Shows Cancer Treatment Effective
January 21, 2011 at 10:09 AM EST
Immunomedics, Inc. (IMMU) announced that repeated therapy cycles of its proprietary antibody, clivatuzumab tetraxetan, labeled with yttrium-90 (Y-90) plus low-dose gemcitabine at 200 mg/m2, extended median overall survival (OS) to 11.8 months, more than double the 5.4 months OS in patients treated with a single cycle. Increased Y-90 doses also improved responses; patients receiving a [...]